| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Hosenkoside G is a naturally occurring compound with anti-tumor activity. Its precise molecular target is not fully defined, but it is known to inhibit the growth of cancer cells. It is believed to exert its effects through mechanisms that disrupt cancer cell proliferation, potentially by interfering with cell cycle progression or inducing apoptosis.
|
|---|---|
| ln Vitro |
In vitro, Hosenkoside G has demonstrated growth-inhibitory activity in A375 melanoma cells. This indicates that the compound has direct antiproliferative effects on cancer cells. Its activity is typically measured by assessing cell viability after treatment with the compound.
|
| ln Vivo |
In vivo, Hosenkoside G's anti-tumor activity has been noted, though detailed efficacy data are limited. As a natural product with in vitro activity, it is a candidate for further in vivo studies to evaluate its potential as an anticancer agent. Its effects on tumor growth in animal models would need to be confirmed.
|
| Enzyme Assay |
In vitro assays for Hosenkoside G typically involve testing its antiproliferative activity against cancer cell lines. Cells are treated with varying concentrations of the compound for 48-72 hours. Cell viability is assessed using a standard assay such as MTT or SRB. The IC50, representing the concentration that inhibits 50% of cell growth, is calculated.
|
| Cell Assay |
Cellular assays are performed using cancer cell lines such as A375 melanoma cells. Cells are cultured in appropriate media and treated with Hosenkoside G at various concentrations. After incubation, cell viability is measured. The compound's effects on cell cycle distribution and apoptosis can also be assessed by flow cytometry.
|
| Animal Protocol |
In vivo studies to evaluate the antitumor activity of Hosenkoside G would be conducted in mouse xenograft models. Mice would be implanted with human cancer cells, and once tumors are established, they would be treated with the compound, likely via intraperitoneal or oral administration. Tumor volume would be measured to assess efficacy.
|
| ADME/Pharmacokinetics |
Hosenkoside G has a molecular weight of 949.13 g/mol and a chemical formula of C47H80O19. As a large, highly glycosylated triterpenoid saponin, its oral bioavailability is expected to be low. It is poorly absorbed and is primarily metabolized by the gut microbiota. Its pharmacokinetic properties are typical of saponins.
|
| Toxicity/Toxicokinetics |
Hosenkoside G is generally well-tolerated in research settings. As a natural product, its toxicity profile is not fully characterized. Preclinical studies would involve standard toxicology assessments to determine its safety margin and potential side effects.
|
| References |
|
| Additional Infomation |
Reports indicate that balsam flowers contain Hosenkoside G, and relevant data is available for reference.
Hosenkoside G is a natural product from Impatiens balsamina L.. It is a baccharane glycoside that possesses anti-tumor activity. It demonstrates growth-inhibitory activity in A375 cells, making it a candidate for cancer research. |
| Molecular Formula |
C47H80O19
|
|---|---|
| Molecular Weight |
949.1267
|
| Exact Mass |
948.529
|
| CAS # |
160896-46-8
|
| PubChem CID |
102004930
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
1044.5±65.0 °C at 760 mmHg
|
| Flash Point |
585.5±34.3 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.624
|
| LogP |
3.29
|
| Hydrogen Bond Donor Count |
13
|
| Hydrogen Bond Acceptor Count |
19
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
66
|
| Complexity |
1660
|
| Defined Atom Stereocenter Count |
24
|
| SMILES |
OC1[C@](CO)(CCC=C(C)CO)CC[C@]2(C)[C@@]1([H])CC[C@@]1([H])[C@@]3(C)CCC([C@@](C)(COC4C(C(C(C(CO)O4)O)O)O)[C@]3([H])CC[C@]12C)OC1C(C(C(C(CO)O1)O)O)OC1C(C(C(CO1)O)O)O
|
| InChi Key |
AJUACYVEKRAXEB-QXJSNOIISA-N
|
| InChi Code |
InChI=1S/C47H80O19/c1-23(17-48)7-6-12-47(21-51)16-15-45(4)24(39(47)60)8-9-29-43(2)13-11-30(65-42-38(35(57)33(55)27(19-50)64-42)66-40-36(58)31(53)25(52)20-61-40)44(3,28(43)10-14-46(29,45)5)22-62-41-37(59)34(56)32(54)26(18-49)63-41/h7,24-42,48-60H,6,8-22H2,1-5H3/b23-7-/t24-,25-,26-,27-,28-,29-,30+,31+,32-,33-,34+,35+,36-,37-,38-,39-,40+,41-,42+,43+,44+,45-,46-,47-/m1/s1
|
| Chemical Name |
(2R,3R,4S,5S,6R)-2-[[(1R,2S,4aR,4bR,6aS,7R,8R,10aR,10bR,12aR)-2-[(2R,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-7-hydroxy-8-(hydroxymethyl)-8-[(Z)-5-hydroxy-4-methylpent-3-enyl]-1,4a,10a,10b-tetramethyl-3,4,4b,5,6,6a,7,9,10,11,12,12a-dodecahydro-2H-chrysen-1-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0536 mL | 5.2680 mL | 10.5360 mL | |
| 5 mM | 0.2107 mL | 1.0536 mL | 2.1072 mL | |
| 10 mM | 0.1054 mL | 0.5268 mL | 1.0536 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
